ArticleBMC biotechnology2026
Development and validation of a comprehensive in vitro organ model for androgenetic alopecia.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMale androgenetic alopecia (AGA) is the most common hair loss disorder. However, research on AGA remains limited, primarily due to the lack of clinical samples and imperfect AGA models incapable of replicating the androgen sensitivity of AGA.
methodsAn AGA organ model was established by optimizing the concentration of dihydrotestosterone (DHT) and simulating AGA pathology through organotypic culture. The model's effectiveness was evaluated using histology, immunohistochemistry, and RNA-seq analysis, focusing on hair follicle (HF) growth, proliferation, apoptosis, key signaling molecules in AGA, stem cell state, and androgen receptor (AR) alterations.
resultsWe determined the optimal DHT concentration for our AGA organ model at 5 × 10
conclusionsOur study presents a novel human in vitro AGA model that closely mirrors the clinical features of AGA in terms of morphology and molecular pathology. Beyond mechanistic research, this model provides a translationally relevant platform for drug evaluation and personalized therapeutic development. By preserving native androgen sensitivity and pathological microenvironment, this work lays a foundation for discovering new regenerative treatments for AGA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.